RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Downregulation of GSDMB by EBV-encoded miR-BART12-3p suppresses killer lymphocyte-mediated pyroptosis in gastric cancer cells.
Downregulation of GSDMB by EBV-encoded miR-BART12-3p suppresses killer lymphocyte-mediated pyroptosis in gastric cancer cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
EBV相关胃癌(EBVaGC)是胃癌(GC)的一种独特亚型,具有特征性的临床病理和分子特征。EBVaGC比EBV阴性胃癌表现出更广泛的淋巴细胞浸润,并表达一系列EBV编码的病毒产物。
然而,EBV阳性GC细胞与肿瘤微环境中免疫细胞之间的相互作用尚不清楚。在此,我们发现EBV下调EBV阳性GC细胞中GSDMB——一种焦亡执行分子——的表达,并使这些细胞能够逃避NK细胞和细胞毒性T淋巴细胞所诱导的GSDMB切割依赖性焦亡。该焦亡主要通过GC细胞中的全长GSDMB异构体(GSDMBiso3)执行。
我们进一步发现,EBV编码的miR-BART12-3p靶向GSDMB 3‘-UTR以下调其在GC细胞中的表达。在体外和体内实验中均证实,抑制miR-BART12-3p可通过触发GSDMB切割诱导的焦亡,增强NK细胞对EBV阳性GC细胞的抗肿瘤效果。
总之,本研究阐明了EBV下调GSDMB以逃逸免疫细胞杀伤的分子机制,并为将基于杀伤淋巴细胞的疗法与miR-BART12-3p抑制剂联合用于治疗EBVaGC提供了理论依据。
Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) is a distinct subtype of gastric cancer (GC) with characteristic clinicopathological and molecular features. EBVaGC exhibits a more extensive lymphocyte infiltration than EBV-negative counterparts, and expresses a range of EBV encoded viral products.
However, the interactions between EBV-positive GC cells and immune cells within the tumor microenvironment are not well understood.
Herein we found that EBV downregulates GSDMB, an executive molecule of pyroptosis, in EBV-positive GC cells and enables these cells to escape GSDMB cleavage-induced pyroptosis by NK cells and cytotoxic T lymphocytes. The pyroptosis is mainly executed through the full length GSDMB isoform (GSDMBiso3) in GC cells.
We further found EBV-encoded miR-BART12-3p targets the GSDMB 3'-UTR to downregulate its expression in GC cells. Inhibition of miR-BART12-3p enhances antitumor efficacy of NK cells against EBV-positive GC cells by triggering GSDMB cleavage-induced pyroptosis, as demonstrated both in vitro and in vivo.
In conclusion, this study elucidates the molecular mechanism by which EBV downregulates GSDMB to evade immune cell killing, and provides a rationale for combining killer lymphocyte-based therapies with a miR-BART12-3p inhibitor for the treatment of EBVaGC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。